id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308293-8y2iaqnl	Singh, Vijay P.	What underlies the benefit of famotidine formulations used during COVID-19?	2020-08-07		.txt	text/plain	775	51	50	This was a retrospective analysis of an inpatient cohort admitted to two hospitals in New York, which found that COVID-19 patients who were treated with famotidine exhibited a lower risk of death or mechanical ventilation as composite outcomes over a 30-day period. However, the current study published in Gastroenterology provides additional value as the previous cohort was much smaller in number, included patients without a proven COVID-19 diagnosis, and lacked a control group. Using in silico molecular docking screens, famotidine has been characterized as potentially being able to bind papain-like protease (PLpro) and 3 chymotrypsin-like protease (Mpro) of SARS-CoV-2 2 5 . This represents weak, nonspecific binding of famotidine to both PLpro and Mpro, and is in contradiction to previous molecular docking studies. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	./cache/cord-308293-8y2iaqnl.txt	./txt/cord-308293-8y2iaqnl.txt